Journal
MOLECULAR THERAPY
Volume 30, Issue 4, Pages 1407-1420Publisher
CELL PRESS
DOI: 10.1016/j.ymthe.2022.02.010
Keywords
-
Categories
Funding
- Roy and Diana Vagelos Precision Med-icine Award
- National Institutes of Health [5P30CA013696, U01 EY030580, U54OD020351, R24EY028758, R24EY027285, 5P30EY019007, R01EY018213, R01EY 024698, R01EY026682, R21AG050437]
- Schneeweiss Stem Cell Fund
- New York State [SDHDOH01-C32590GG-3450000]
- Spark Therapeutics
- Abeona Therapeutics, Inc., Fund
- Foundation Fighting Blindness New York Regional Research Center [TA-GT-0321-0802-COLU-TRAP]
- Nancy Kobi Karp
- Crowley Family Funds
- Rosenbaum Family Foundation
- Alcon Research Institute
- Gilbert Family Foundation
- Research to Prevent Blindness (RPB) Physician-Scientist Award
- RPB, New York, NY, USA
Ask authors/readers for more resources
This study presents a CRISPR-based gene modification therapy for autosomal dominant retinitis pigmentosa, which has been validated in a humanized mouse model, demonstrating the effectiveness of the treatment and its potential application in other genetic diseases.
Mutations in rhodopsin (RHO) are the most common causes of autosomal dominant retinitis pigmentosa (adRP), accounting for 20% to 30% of all cases worldwide. However, the high degree of genetic heterogeneity makes development of effective therapies cumbersome. To provide a universal solution to RHO-related adRP, we devised a CRISPR-based, mutation-independent gene ablation and replacement (AR) compound therapy carried by a dual AAV2/8 system. Moreover, we developed a novel hRHO(C110R)/hRHO(WT) humanized mouse model to assess the AR treatment in vivo. Results show that this humanized RHO mouse model exhibits progressive rod-cone degeneration that phenocopies hRHO(C110R)/hRHO(WT) patients. In vivo transduction of AR AAV8 dual vectors remarkably ablates endogenous RHO expression and overexpresses exogenous WT hRHO. Furthermore, the administration of AR during adulthood significantly hampers photoreceptor degeneration both histologically and functionally for at least 6 months compared with sole gene replacement or surgical trauma control. This study demonstrates the effectiveness of AR treatment of adRP in the human genomic context while revealing the feasibility of its application for other autosomal dominant disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available